Previous 10 | Next 10 |
2023-11-07 09:57:20 ET More on Inozyme Pharma Endpoints Unzipped: Inozyme's INZ-701 Twist In The Plot Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma For furthe...
– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency ex...
2023-10-27 17:09:46 ET Gainers: Coherus BioSciences ( CHRS ) +16% . 2U ( TWOU ) +6% . Sarepta Therapeutics ( SRPT ) +5% . Noodles & Company ( NDLS ) +4% . Intuitive Machines ( LUNR ) +4% . Losers: NKGen Biotech ( NK...
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
2023-10-23 17:42:52 ET Gainers: Redfin ( RDFN ) +15% . Agilysys ( AGYS ) +11% . Medpace Holdings ( MEDP ) +5% . HomeStreet ( HMST ) +5% . IDEAYA Biosciences ( IDYA ) +5% . Losers: CareDx ( CDNA ) -8% . A...
2023-10-11 17:30:06 ET Gainers: COMPASS Pathways ( NASDAQ: CMPS ) +5% . Inozyme Pharma ( INZY ) +4% . CommScope Holding ( COMM ) +4% . FTAI Infrastructure ( FIP ) +3% . Aemetis ( AMTX ) +3% . Losers: Lottery ( ...
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) tr...
BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...
News, Short Squeeze, Breakout and More Instantly...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation...